Lifang Pharmaceutical released its 2026 interim report. Total operating revenue was 684 million yuan, down 6.58% from the same period last year. Net profit attributable to the parent company was 88.2051 million yuan, down 2.24% year-on-year. Net cash inflow from operating activities was 162 million yuan. The asset-liability ratio was 24.28%, gross margin was 66.44%, return on equity was 4.79%, and diluted earnings per share was 0.39 yuan. The company had 15,200 shareholders, and the top ten shareholders held 64.10% of the total share capital.
Hefei Lifeon Pharmaceutical Co LtdNet profit and revenue declined year-on-year in interim report.
